Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Partial Oral Therapy for Osteomyelitis and Endocarditis. Reply

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Application of High-Sensitivity Troponin in Suspected Myocardial Infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Long-Term Outcomes of Partial Oral Treatment of Endocarditis

    Research output: Contribution to journalLetterResearch

  5. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Fracture risk in women with type II diabetes. Results from a historical cohort with fracture follow-up

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Vertebral fracture assessment by dual X-ray absorptiometry: reply to comments by Fechtenbaum et al

    Research output: Contribution to journalComment/debateResearchpeer-review

  • Kenneth W Lyles
  • Cathleen S Colón-Emeric
  • Jay S Magaziner
  • Jonathan D Adachi
  • Carl F Pieper
  • Carlos Mautalen
  • Lars Hyldstrup
  • Chris Recknor
  • Lars Nordsletten
  • Kathy A Moore
  • Catherine Lavecchia
  • Jie Zhang
  • Peter Mesenbrink
  • Patricia K Hodgson
  • Ken Abrams
  • John J Orloff
  • Zebulun Horowitz
  • Erik Fink Eriksen
  • Steven Boonen
  • NN NN
View graph of relations
BACKGROUND: Mortality is increased after a hip fracture, and strategies that improve outcomes are needed. METHODS: In this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigned to receive placebo. The infusions were first administered within 90 days after surgical repair of a hip fracture. All patients received supplemental vitamin D and calcium. The median follow-up was 1.9 years. The primary end point was a new clinical fracture. RESULTS: The rates of any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a 35% risk reduction (P = 0.001); the respective rates of a new clinical vertebral fracture were 1.7% and 3.8% (P = 0.02), and the respective rates of new nonvertebral fractures were 7.6% and 10.7% (P = 0.03). In the safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6%) and 141 of 1057 patients in the placebo group (13.3%) died, a reduction of 28% in deaths from any cause in the zoledronic-acid group (P = 0.01). The most frequent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain. No cases of osteonecrosis of the jaw were reported, and no adverse effects on the healing of fractures were noted. The rates of renal and cardiovascular adverse events, including atrial fibrillation and stroke, were similar in the two groups. CONCLUSIONS: An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and improved survival. (ClinicalTrials.gov number, NCT00046254.).
Original languageEnglish
JournalNew England Journal of Medicine
Volume357
Pages (from-to)nihpa40967
ISSN0028-4793
DOIs
Publication statusPublished - 2007

ID: 32571674